AQST240816C2500
- 0.70
- 0.000.00%
Aquestive Therapeutics Newsroom
Aquestive Therapeutics (NASDAQ:AQST) Delivers Shareholders Favorable 85% Return Over 1 Year, Surging 23% in the Last Week Alone
Aquestive Therapeutics, Inc. (NASDAQ:AQST) shareholders might be concerned after seeing the share price drop 22% in the last quarter. While that might be a setback, it doesn't negate the nice
Express News | JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
JMP Securities analyst Jason Butler maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 38
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film.Anaphylm
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $7
Lake Street analyst Thomas Flaten maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and adjusts the target price from $8 to $7.According to TipRanks data, the analyst has a success rate o
Aquestive Gains After Initial Data for Allergy Candidate
Express News | Aquestive Therapeutics: Sees Filing Nda Shortly After Completion of Pediatric Study of Anaphylm
Express News | Aquestive Therapeutics Inc: On Track to Complete Anaphylm Supportive Clinical Studies, Expects to Request Pre-Nda Meeting With FDA in Q3
Express News | Aquestive Therapeutics Inc: Reports Positive Topline Data From Temperature / Ph Study of Anaphylm™ (Epinephrine) Sublingual Film
Investors in Aquestive Therapeutics (NASDAQ:AQST) Have Unfortunately Lost 36% Over the Last Five Years
Express News | Aquestive Therapeutics To Join Russell 3000 And Russell 2000 Indexes Effective June 28, 2024
Aquestive Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Aquestive Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright analyst Ram Selvaraju maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of
Express News | Aquestive Therapeutics Appoints Cassie Jung As COO
Aquestive Therapeutics Appoints Cassie Jung Oper Chief >AQST
Aquestive Therapeutics Appoints Cassie Jung Oper Chief >AQST
Express News | Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
Express News | Aquestive Therapeutics Announces Two Encore Poster Presentations Highlighting Positive PK And PD Data From Clinical Studies For Anaphylm (Epinephrine) Sublingual Film At The Eastern Allergy Conference From May 30 To June 2
With A 27% Price Drop For Aquestive Therapeutics, Inc. (NASDAQ:AQST) You'll Still Get What You Pay For
Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares have retraced a considerable 27% in the last month, reversing a fair amount of their solid recent performance.
CRSP, NYMT and SBRA Are Among After Hour Movers
Aquestive Therapeutics Initiated at Outperform by Leerink Partners
Aquestive Therapeutics Initiated at Outperform by Leerink Partners